Shanghai Bao Pharmaceuticals Co Ltd Class H 2659
HKEX · Hong Kong SAR China · Health Technology
HKD 12.08-0.23 (-1.87%)
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
These ratios divide the lines in the statements below by the current price; both inputs of every value are visible on this page. The P/E on the overview comes from the same calculation. P/E and P/S are left blank for loss-making companies or where revenue is not reported. Not investment advice.
| FY2025 | FY2024 | FY2023 | |
|---|---|---|---|
| Revenue | HKD 54.76M | HKD 6.54M | HKD 7.71M |
| Revenue growth (YoY) | +737.2% | -15.2% | — |
| Cost of Revenue | MakklerPRO | MakklerPRO | MakklerPRO |
| Gross Profit | MakklerPRO | MakklerPRO | MakklerPRO |
| Gross margin | MakklerPRO | MakklerPRO | MakklerPRO |
| Operating expenses |
| MakklerPRO |
| MakklerPRO |
| MakklerPRO |
| Operating Income | MakklerPRO | MakklerPRO | MakklerPRO |
| Operating margin | MakklerPRO | MakklerPRO | MakklerPRO |
| EBITDA | MakklerPRO | MakklerPRO | MakklerPRO |
| Pre-tax income | MakklerPRO | MakklerPRO | MakklerPRO |
| Income tax | MakklerPRO | MakklerPRO | MakklerPRO |
| Net Income | -HKD 440.37M | -HKD 386.98M | -HKD 178.52M |
| Net margin | MakklerPRO | MakklerPRO | MakklerPRO |
| Diluted EPS | MakklerPRO | MakklerPRO | MakklerPRO |
| Diluted shares | MakklerPRO | MakklerPRO | MakklerPRO |
| FY2025 | FY2024 | FY2023 | |
|---|---|---|---|
| Cash & equivalents | MakklerPRO | MakklerPRO | MakklerPRO |
| Total Current Assets | MakklerPRO | MakklerPRO | MakklerPRO |
| Total Assets | HKD 2.47B | HKD 1.45B | HKD 1.08B |
| Total Current Liabilities | MakklerPRO | MakklerPRO | MakklerPRO |
| Total Liabilities | MakklerPRO | MakklerPRO | MakklerPRO |
| Total debt | MakklerPRO | MakklerPRO | MakklerPRO |
| Total Equity | MakklerPRO | MakklerPRO | MakklerPRO |
| FY2025 | FY2024 | FY2023 | |
|---|---|---|---|
| Cash from Operations | -HKD 200.58M | -HKD 233.38M | -HKD 156.06M |
| Capital expenditure | MakklerPRO | MakklerPRO | MakklerPRO |
| Free cash flow | MakklerPRO | MakklerPRO | MakklerPRO |
| Cash from Investing | MakklerPRO | MakklerPRO | MakklerPRO |
| Cash from Financing | MakklerPRO | MakklerPRO | MakklerPRO |
Standardised statements compiled from the company's annual and interim reports. The "LTM" column covers the last four reported quarters; balance-sheet lines in it are from the latest quarter. Lines the company does not report are left blank rather than approximated. Not investment advice. The company reports in CNY; every figure is converted to HKD at the exchange rate of its own period end (the latest rate for LTM), so it can be compared with the share price.